Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details VITALITY-ALS, a Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity and other measures of respiratory function in patients with ALS, began in July 2015 and results are expected in the third quarter of 2017.  Tirasemptiv is Cytokinetic's lead drug candidate in development
Additional Relevant Details "We look forward to reporting results in the second half of 2017."
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vitality-als, Phase 3 Study, Tirasemptiv, Als